|Bid||0.00 x 4000|
|Ask||0.00 x 800|
|Day's range||15.14 - 15.99|
|52-week range||14.78 - 41.48|
|Beta (5Y monthly)||1.14|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||49.27|
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. In Q1 Esperion earned $8 million, over four times the $1.8 million of Q1 2020, fueled by $6.4 million in product revenue (royalty revenue came in at roughly $600,000).